#libtayo

FDA approves first treatment Libtayo (cemiplimab-rwlc) for advanced form of the second most common skin cancer

FDA approves first treatment for advanced form of the second most common skin cancer

New drug targets PD-1 pathway

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative…

U.S. Food & Drug Administration News: FDA approves first treatment for advanced form of the second most common skin cancer

SILVER SPRING, MD – The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.  This is the first FDA approval of a drug specifically for advanced CSCC.

Libtayo works by…